Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer

While adjuvant treatment with the selective-estrogen receptor modulator (SERM) tamoxifen has been the standard of care for pre-menopausal patients with hormone receptor (HR) positive breast cancer, recent trials showed a benefit of aromatase inhibitors (AI) and ovarian function suppression (OFS) for...

Descripción completa

Detalles Bibliográficos
Autores principales: Record, Helena, Clelland, Elle, Rothschild, Harriet T., Kaur, Mandeep, Chien, A. Jo, Melisko, Michelle, Rugo, Hope S., Mujir, Firdows, Huppert, Laura, Mukhtar, Rita A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603127/
https://www.ncbi.nlm.nih.gov/pubmed/37884561
http://dx.doi.org/10.1038/s41523-023-00594-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603127/
https://www.ncbi.nlm.nih.gov/pubmed/37884561
http://dx.doi.org/10.1038/s41523-023-00594-3

Ejemplares similares